ognizant Communication Corporation

ONCOLOGY RESEARCH
AN INTERNATIONAL JOURNAL
INCORPORATING ANTI-CANCER DRUG DESIGN

AUTHOR AND SUBJECT INDEXES

VOLUME 15

Author Index

Abe, T., 139
Abrial, C., 431
Adams, J., 281
Albanese, C., 113
Alves, P. A. G., 385
Amarantidis, K., 445
Anderson, G. R., 233
Ardizzoni, A., 39
Ather, A., 69

Bae, Y.-S., 327
Baek, K.-H., 161
Baguley, B. C., 291, 351
Barrachina, I., 129
Baumann, R. P., 313
Behnam-Motlagh, P., 423
Belli, C., 169
Bergoc, R., 301
Bergström, P., 423
Berrieman, H. K., 441
Bianchi, N., 373
Biava, P. M., 399
Bizzarri, M., 399
Bloomer, W. D., 219
Boratynski, J., 183
Borgatti, M., 373
Boyd, D. D., 265, 373
Bustuoabad, O. D., 169
Bustuoabad, V. de los A., 169

Cabrespine, A., 431
Cai, Q., 490
Camerano, G. V., 169
Campbell, A., 441 
Campisi, G., 249
Cao, J., 487
Capogreco, M., 249
Carinci, F., 249
Castel, V., 393
Cavenee, W. K., 456
Cawkwell, L., 441
Chang, E. H., 463
Chang, G., 501
Chapuis, J.-C., 11
Chatzaki, E., 445
Che, G.-W., 472
Chen, C.-L., 468
Chen, J., 501
Chen, Kan, 500
Chen, Ke, 476
Chen, L., 469
Chen, M. L., 465
Chen, M., 503
Chen, N., 233
Chen, Q., 492
Chen, S., 472
Chen, X., 490
Chen, Y., 503
Chen, Z., 489
Cheng, S., 460
Cheng, W.-P., 485
Ching, L.-M., 351
Chollet, P., 431
Cocca, C., 301
Cooper, L., 459
Cortes, D., 129
Costa, H., 169
Crescenti, E., 301
Cricco, G., 301
Croci, M., 301
Csömör, S., 215
Cuadrillero, C., 129
Cure, H., 431
Cutts, S. M., 199

Dabrowska, K., 183
da Rocha, A. B., 385
Deaver, M., 49
de Jong, S., 151
Deng, M.-Q., 471
Deng, Y., 481
DePedro, N., 129
De Rosa, G., 249
Dévényi, L., 215
de Vries, E. F. J., 151
di Gianni, P., 169
Ding, J., 461
Ding, W., 489
Ding, Y. Q., 478
Doubek, D. L., 11, 59
Dran, G., 169
Drummond, C. J., 351
Du, W., 503
Du, Y., 493
Du, Z., 468
Ducki, S., 11
Durando, X., 431
Dutt, S. S., 233
Dvorak, H., 455

Edakuni, N., 107
Engers, R., 257

Fabbri, E., 373
Falaschini, S., 249
Fan, L., 501
Fan, T.-P., 462
Fang, L., 501
Farina, A., 249
Favoni, R., 39
Feng, L.-F., 497, 498, 499
Feng, X., 475
Feng, X. L., 478
Feng, X. L., 479
Feng, Y., 486
Ferguson, J., 87
Ferriere, J. P., 431
Finn, P. W., 463
Florl, A. R., 257
Fokt, I., 265
Frati, L., 399
Freedman, R. S., 49
Frosi, A., 399
Fu, J.-K., 472
Fu, L., 486
Fukiki, M., 139

Gallo, M. A., 113
Gambari, R., 69, 373
Gao, L., 497
Gao, P., 333
Gao, R., 475
Gao, S.-Y., 484, 485, 486*
Gao, Y., 477, 481
Georgoulias, V., 445
Getoff, N., 295
Giorgi, G., 69
Girgis, A., 281 
Górski, A., 183
Grankvist, K., 423
Grass, L. B., 385
Grau, E., 393
Grivicich, I., 385
Grossi, F., 39
Guarnera, A., 409
Guo, A., 467
Guo, L., 471
Gutiérrez, A., 301

Han, W. N., 478, 479
Hang, J., 475
Hayashi, S., 365
He, G., 502
He, J., 475
He, Q., 501, 502
He, X., 502
He, Z., 489
He, Z. X., 465
Henriksson, R., 423
Henriques, J. A., 385
Herald, D. L., 11, 59
Hernández, P., 129
Hernández-Martí, M., 393
Hirst, D. G., 81
Hong, M.-H., 471
Hospers, G. A. P., 151
Hou, L., 488
Hu, H., 469
Hu, W., 49
Hu, Y., 502
Huang, B.-H., 477, 481
Huang, W., 496
Huang, W. L., 491
Hubay, M., 215
Hung, M.-C., 456

Ikeda, Y., 189
Inayama, M., 107
Inoue, R., 139
Isturiz, M. A., 169

Jahreis, G. P., 233
Jamaluddin, Md. S., 265
Jeong, S.-J., 161
Ji, C., 4861
Ji, H., 484
Ji, Q., 500
Ji, Y.-B., 484, 485, 486*
Jiang, J.-D., 457
Jiang, M., 472
Jiang, S., 494
Jin, J., 497
Jin, X., 496*
Johansson, A., 423
Johansson, D., 423
Johnston, D. A., 49 
Ju, C., 488

Kakiuchi, S., 107
Kaklamanis, L., 445
Kakolyris, S., 445
Karayiannakis, A., 445
Kavanagh, J. J., 49
Kawai, Y., 189
Kawase, I., 365
Kayser, G. B., 385
Kelland, L. R., 87
Khan, M. T. H., 69
Kieda, C., 351
Kim, C.-M., 161
Kim, Keun Sik, 343
Kim, Kil-Soo, 333
Kim, M.-O., 333
Kim, Soon-Hee, 327
Kim, Sung-Hyun, 333
Kim, Y. H., 327
Kimba, Y., 139
Kimura, S., 1
Kobayashi, H., 139
Kohno, K., 139
Koizumi, M., 1
Kong, Q., 484
Kou, B., 239
Kuroda, J., 1
Kwiatkowski, F., 431

Lambertini, E., 69
Lambris, J. D., 21
Lampronti, I., 69, 373
Laner, T., 257
Lang, L., 486
Laughton, C. A., 95
Lazzaroni, S., 399
Lee, B. W., 327
Lee, C.-W., 161
Lee, H.-T., 333
Lee, S.-R., 333
Lee, T.-H., 333
Leheurteur, M., 431
Lei, X.-Y., 497, 498, 499
Levovich, I., 199
Lewis, J. S., 113
Li, D.-B., 472
Li, Dian-dong, 475
Li, Dongjie, 495
Li, Hong, 478, 479
Li, Hong-wei, 481
Li, Jianfang, 490
Li, Jiyu, 492
Li, Jun, 463, 492, 496
Li, L.-R., 469
Li, N., 495
Li, W., 481
Li, X. F., 465
Li, X.-M., 470
Li, Yan, 491
Li, Yan, 494*, 496
Li, Yin, 472
Li, Yulin, 239
Liang, W.-J., 468, 471
Liang, X., 465
Liao, D.-F., 497, 498, 499
Lin, C., 465
Lin, J., 467
Lin, Z., 465
Liu, Bingya, 490
Liu, Bo, 476
Liu, G. T., 466
Liu, Jianwen, 492
Liu, Jun, 469
Liu, L., 496
Liu, L.-X., 472
Liu, Qiao, 476
Liu, Qi, 493, 494, 495
Liu, Q.-C., 471
Liu, R.-Y., 491
Liu, W., 500
Liu, Xiaorong, 489
Liu, Xiao-yun, 473
Liu, Xinfan, 497
Liu, Xiu-jun, 473
Livraghi, T., 399
Lo Muzio, L., 249
Lombardi, M. G., 169
Loncarek, J., 151
Loprevite, M., 39
Lou, J., 467
Lou, Y.-J., 483, 484
Lu, H., 493, 494, 496
Lu, W., 502
Lu, Y., 476
Lu, Z., 493, 494*, 496*
Luo, B., 477, 481
Luo, P., 502*
Lv, H., 489

Müller, M., 257
Ma, H., 492, 493*, 494, 495*, 496*
Ma, J., 494, 496
Ma, W., 465
Maekawa, T., 1
Mai, H.-Q., 471
Marasco, W. A., 458
Maraveyas, A., 441
Marshall, E., 291
Martín, G., 301
Martínez, F., 393
McKeon, F., 161
Medina, V., 301
Meijer, C., 151
Meiss, R. P., 169
Meloni, F., 399
Meng, K., 492, 493, 494*, 496*
Meng, P., 482
Meng, Y., 59
Mesnil, M., 151
Miao, Q., 474
Micheli, A., 445
Milasi, A., 409
Min, H.-Q., 471
Missailidis, S., 95
Modi, C., 95
Mohamad, N., 301
Mouret-Reynier, M. A., 431 
Mu, X., 475
Muguruma, H., 107
Mulder, N. H., 151

Núñez, M., 301
Nair, R. R., 265
Nakataki, E., 107, 365
Narviatz, M., 169
Nevozhay, D., 183
Nie, Q., 472
Nishikubo, N., 107
Niu, J., 467
Nogawa, M., 1
Nudelman, A., 199

Ohno, O., 189
Ohtsuka, S., 107
O'Kane, S. L., 441
Oltra, S., 393
Opolski, A., 183
Orellana, C., 393
Ouyang, Z., 473, 474

Pan, D.-X., 470
Pan, Q., 469
Pandolfi, A., 39
Papadopoulou, M. V., 219
Pappas, I. S., 21
Park, B.-J., 333
Park, H., 333
Park, J.-W., 161
Park, K. H., 327
Park, Y. S., 343
Patai, K., 215
Pedone, C., 373
Peláez, F., 129
Penault-Llorca, F., 431
Penketh, P. G., 313
Penolazzi, L., 69
Pestell, R. G., 113
Petrelli, N. J., 233
Pettit, G. R., 11, 59
Pettit, R. K., 59
Pezzetti, F., 249
Phillips, D. R., 199
Pillay, V., 199
Piva, R., 69
Priebe, W., 265

Qian, X., 476
Qin, H.-D., 471
Qu, Y., 490
Quan, Z., 492

Raghavakaimal, S., 457
Ran, Y., 469
Rayburn, E., 475
Reddy, C. B., 351
Regner, A., 385
Renis, M., 409
Rephaeli, A., 199
Robins, D. J., 87
Rodriguez-Bigas, M. A., 233
Rogers, P. M., 87
Romanelli, A., 373
Rosenzweig, H. S., 219
Royo, I., 129
Rubini, C., 249
Ruddock, M. W., 81
Ruggiero, R. A., 169
Ryoo, Z.-Y., 333

Sakurai, K., 189
Sartorelli, A. C., 313
Sato, K., 1
Saviano, M., 373
Schere-Levy, C., 169
Schmidt, J. M., 11
Schooltink, M. A., 351
Schulz, W. A., 257
Schwartsmann, G., 385
Scifo, C., 409
Scolaro, T., 39
Segawa, H., 1
Semino, C., 39
Sen, S., 49
Seow, H. A., 313
Shang, B., 474
Shao, K., 475
Shao, R.-G., 456
Shi, Q., 492, 493*, 494*, 495*, 496*
Shi, S., 475
Shi, Yi-kang, 475
Shi, Yingai, 239
Shi, Z., 494
Shima, Y., 189
Shin, H.-J., 161
Shu, G., 468
Shyam, K., 313
Sibbritt, D., 281
Sies, H., 462
Sinatra, F., 409
Sluiter, W. J., 151
Smith, L., 441
Sone, S., 107, 365
Song, X., 476
Spathari, N., 445
Spencer, D. M. S., 199
Stevens, A. M., 59
Stevens, M. F. G., 95
Stoler, D. L., 233
Suh, J.-G., 333
Sun, G., 493, 495*, 496
Sun, H., 466
Sun, L., 469
Sun, S.-H., 481
Switala-Jelen, K., 183
Szczaurska, K., 183

Tachibana, I., 365
Tang, S.-S., 497, 499
Thomas, T., 113
Thomas, T. J., 113
Tian, F.-Z., 491
Tiseo, M., 39
Tomimoto, H., 107
Tormo, J. R., 129
Trapani, V., 95
Trichas, M., 445
Tsiftsoglou, A. S., 21
Tu, Y., 498

Umezawa, K., 189

Vaalburg, W., 151
van Dillen, I. J., 151
van Rooijen, N., 169
Verschraegen, C. F., 49
Vijayanathan, V., 113
Vizirianakis, I. S., 21

Wan, D.-S., 469
Wang, D., 465
Wang, Heng, 265
Wang, Hui, 475
Wang, L., 479
Wang, L., 487, 488*
Wang, N., 495
Wang, Q. W., 465
Wang, S., 479
Wang, Wei, 475
Wang, Wen, 467
Wang, Xiao-ying, 500
Wang, Xi-cai, 503
Wang, Xinrui, 239
Wang, X.-F., 477
Wang, Yi-jun, 468
Wang, Yu-feng, 475
Wang, Yun, 477
Wang, Yunwei, 490
Wang, Yan, 496
Wang, Z., 503
Watanabe, K., 189
We, C., 468
Weinstein, I. B., 460
Wen, J., 467
Wietrzyk, J., 183
Winters, M. S., 21
Woon, S.-T., 351
Wu, B., 494, 495
Wu, J., 501
Wu, J. L., 139
Wu, L., 467
Wu, S., 239
Wu, Y.-D., 483, 484
Wu, Z., 503

Xia, J., 239
Xiang, Y.-Q., 471
Xiong, W., 465
Xu, G., 497
Xu, S.-F., 486
Xu, Y., 503

Yan, C., 498
Yang, Bao-feng, 484
Yang, Bo, 501, 502*
Yang, H., 481
Yang, M., 465
Yang, S., 467
Yang, W., 497
Yang, Xiaochun, 502
Yang, Xiao-feng, 500
Yang, Xing, 469
Yang, Xuyu, 479
Yang, Zhi-hong, 488
Yang, Zhihua, 469
Yano, S., 107, 365
Yao, D., 473
Yao, K., 478, 479
Yao, Y.-L., 468
Ye, L., 467
Yin, D., 481
Yin, F., 481
Yokota, A., 1
Yoon, S.-H., 327
Youm, C.-A., 333
Yu, Lei, 486
Yu, Long, 469
Yu, Y., 489
Yuan, Q., 468
Yuan, S., 501
Yuan, Z., 497
Yuasa, T., 1
Yue, W., 487, 488
Yue, W., 488

Zafra-Polo, M. C., 129
Zelkó, R., 215
Zeng, J., 468
Zeng, Y.-X., 471
Zhan, Q., 455
Zhang, B., 486
Zhang, C., 475
Zhang, F., 487, 488
Zhang, H. J., 478
Zhang, Helong, 365
Zhang, Hongying, 494, 496
Zhang, J., 493
Zhang, Sen, 475
Zhang, Shu-ping, 468
Zhang, Shuren, 465
Zhang, Wei, 457
Zhang, Wenjian, 467
Zhang, W.-D., 468
Zhang, X., 488
Zhang, X.-J., 484
Zhang, X.-S., 471
Zhang, Yuan-yuan, 486
Zhang, Yan, 492
Zhangh, Y., 465
Zhao, C., 475
Zhao, P., 477, 481
Zhao, Q., 476
Zhao, Xilu, 469
Zhao, Xinhua, 476
Zhe, B.-Y., 497, 499
Zhen, Y., 458, 472, 473*, 474*, 475*
Zheng, R., 365
Zheng, S., 482
Zheng, X., 500
Zhong, M., 497, 498, 499
Zhou, C., 465
Zhou, H., 496
Zhou, Min, 489
Zhou, Ming, 487, 488
Zhou, Q., 467, 472
Zhou, W., 478, 479
Zhou, X., 492. 493*, 494*, 495, 496*
Zhou, Z., 493, 496
Zhu, Wei, 481
Zhu, Wen, 472
Zhu, Z., 490
Zue, G., 491
 

*Indicates the author appears in more than one abstract on that page.

Subject Index

Acquired resistance, 107
Adenocarcinoma, 215
Adenylate cyclase toxin, 423
Administration routes, 183
Adriamycin, 199
Aegle marmelos, 69
Agelastatin A, 11
AGT, 313
Alveolar hemorrhage, 107
Amide, 87
AN9, 199
Anastrozole, 431
Aneuploidy, 49
Angiogenesis, 139, 239
Angiostatin, 343
Annonaceous acetogenins, 129
Antiangiogenesis, 343
Anticancer, 11
Anticancer activities, 59
Anticancer activity, 183
Anticancer drug, 327
Antimelanoma, 87
Antimicrobial activities, 59
Antitumor, 351
Apoptosis, 327, 385, 423, 441
Apoptotic cell death, 161
Artery, 81
ATF-2, 113

Bacteriophage HPA1, 183
Bacteriophage T4, 183
bcl-2, 249
Biological response modifiers, 399
Bioreductive drugs, 219
Bisphosphonate, 1
Breast cancer, 69, 431
5-Bromo-2´-deoxy-uridine (BrdU), 333
Bystander effect, 151

Cancer, 249, 281
Capparidaceae, 59
Carbamoylation, 313
Caspase-mediated cleavage, 161
Caspases, 385
CD9, 365
Cell cycle, 409
Cell cycle length, 291
Cell lines, 39
Centrosomal kinase, 49
Chloroethylation, 313
CI-994, 39
Circular dichroism, 95
Cisplatin, 423
CloretazineTM, 313
Colon cancer cells, 385
Colorectal cancer, 445 
Combined therapy, 39
Complementary and alternative therapies, 281
COX-2, 139
Cox analysis, 249
CPT-11/5-FU combination, 385
Cyclin D1, 113
Cysteaminylphenol, 87
Cytotoxic activity, 129
Cytotoxicity, 423

Deacetylase inhibitors, 39
Decoy, 69
DHMEQ, 189
Diabetes, 301
Differentiation, 21
Differentiation factors, 399
Dimethylbenzanthracene (DMBA), 333
DMXAA, 351
DNA adducts, 199
DNA binding, 95
DNA methylation, 257
DU145, 409
 

 

Emblica officinalis, 69
Embryo, 399
Endostatin, 343
Endothelial, 351
Energy dispersive X-ray spectroscopy, 215
Enzyme inhibitor, 327
E-selectin, 189
Estradiol, 113
Estrogen receptor a, 69
Euchrestaflavanone B, 327
Exemestane, 431
Extracellular superoxide dismutase (EC-SOD), 333

Flavones, 59
Fluorescence, 95
Folic acid (vitamin B11), 295
Formaldehyde, 199
Ganciclovir, 151
Gap junctional intercellular communication, 151
Gastric cancer, 441
Gene expression, 265
Gene silencing, 257
Gene therapy, 239, 373
Gene transcription, 373
Genomic instability, 233
Geranylgeranylation, 1
Gifitinib, 107
Glibenclamide, 301
Gynandropis gynandra, 59

Head and neck, 249
Hepatocellular carcinoma, 399
Herpes simplex virus thymidine kinase, 151
HIF-1H, 139
Human prostate cancer, 409
Human RD/TE-671 cells, 21
HUVEC, 189
Hydrodynamics-based transfection, 343
Hymenidin, 11
8-Hydroxy-2´-deoxyguanosine (8OH-dG), 333
Hypoxia, 139

ICAM-1, 189
Ileum, 81
Immunoblotting, 409
Immunohistochemistry, 441, 445
Inducer binding protein, 21
Inducers, 21
Inflammation, 169
Instability events, 233
Interaction, 219
Inter-(simple sequence repeat) PCR, 233
Intramolecular electron transfer, 295
Invasion, 365

Kinetics of FA, FNA, and MTX, 295

Letrozole, 431
Lisofylline, 81
Liver metastasis, 365
Lung cancer, 39, 107
Lupeol, 69
Lymphoid, 351

Malignant ascites, 365
Mammary tumors, 301
Marine sponge, 11
MCF-7 cells, 113
Medicinal plants, 69
Mesothelioma, 423
Mitochondrial complex I, 129
Mitochondrial membrane potential, 385
Mitotic checkpoint proteins, 161
Multidrug resistance, 151
Murine erythroleukemia (MEL) cells, 21
Myoma, 215

Negative feedback oscillation, 291
Neuroblastoma development, 393
NF-kB, 139, 189, 351
N-Nitroso-N-methylurea, 301

Ovarian neoplasm, 49
Overall survival, 431

p53, 151
Patients, 281
Pentoxifylline, 81
Peptide nucleic acids (PNA), 373
Phenylephrine, 81
Phosphor/sulphur ratio, 215
PNA-DNA chimeras, 373
Polyamines, 113
Polycyclic acridine derivatives, 95
Polyploidy, 161
Preclinical investigation, 39
Probability mechanism, 291
Proliferation, 365
Propolis, 409
Prostate cancer, 1
Prostate carcinoma, 257
Protein kinase CKII, 327
Pulse radiolysis of folic acid, 295

Ras, 1
Rats, 301
Resistance, 199
Resveratrol, 409
Retreatment, 107
Retrotransposon, 257
Retroviral vector, 239

SDHB gene, 393
Small-cell lung cancer, 423
Smooth muscle, 81
Soluble receptor, 239
Sp1, 265, 373
Spectrophotometric analysis, 95
Stem cells, 399
STK15/Aurora-A/BTAK, 49
Stomach, 441
Streptozotocin, 301
Strong DNA intercalators, 219
Structure-activity relationships, 129
Succinate dehydrogenase, 393
Sulfonylhydrazine prodrugs, 313
Survival, 249

Tamoxifen, 431
12-O-Tetradecanoylphorbol-13-acetate (TPA), 333
Thermal denaturation, 95
Topoisomerase II, 199
Topoisomerases, 219
Transcription, 265
Transcription factor decoy, 373
Transgenic mice, 333
Transmission electron microscopy, 409
Triplex DNA, 95
Tumor aggressiveness, 169
Tumor growth, 239
Tumor markers, 257
Tumor transition zone, 169
Tyrosinase, 87

Urokinase-type plasminogen activator receptor (uPAR), 265, 373
Utilization, 281
UV, 95

Vascular endothelial growth factor (VEGF), 139, 239, 445
Vascularization, 169
VCAM-1, 198

X-chromosome inactivation, 257

Zoledronic acid, 1